Share your research articles, interpretations and experiences here. Let us know how these studies affect you and your decisions.
Posted on: Jun 23, 2020 09:40AM
The HER2CLIMB-02 trial is enrolling people diagnosed with advanced-stage HER2-positive breast cancer:
The HER2CLIMB-02 trial (https://clinicaltrials.gov/ct2/show/NCT03975647) is looking to see if Tukysa (chemical name: tucatinib) given in combination with Kadcyla (chemical name: T-DM1 or ado-trastuzumab emtansine) will offer more benefits than Kadcyla alone in people diagnosed with:
The HER2CLIMB-02 trial is being conducted at multiple sites around the world and the United States. For a complete list of sites, visit www.her2climb.com.
For more information on detailed eligibility requirements or to enroll